Researchers at Stanford have developed a microparticle-based vaccine that in a single shot enables enhanced activation of CD8+ and/or CD4+ T cells to fight against infectious diseases and cancer.
Researchers at Stanford and the Chan Zuckerberg Biohub have discovered cross reactive, broadly neutralizing human antibodies against all serotypes of dengue virus.
Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed PMD (Protect, Modify, Deprotect), an immunofocusing strategy that can be used in vaccine development for the generation of antibodies targeting a specific epitope.
Stanford researchers have developed one of the smallest, active translational enhancers that can be adapted to control gene regulation. The translation enhancer is a short RNA stem-loop structure isolated from a Hox gene.
Stanford researchers have discovered that ribonucleoside vanadyl complexes can be used as an additive in transcription reactions resulting in ~2-fold increased yield.
RNA replication and amplification have broad applications across biomedicine, but current methods are limited by a reliance on inefficient, multi-step protocols.
Stanford researchers have developed a new class of materials that enable new strategies for the efficient delivery of messenger RNA (mRNA) into cells and animals. The delivery materials are easily prepared (2 steps), stable and readily tuned.
Stanford researchers in Professor Rhiju Das's lab have devised a method called RNAMake to optimize nucleic acids, such as aptamers and messenger RNAs, and enhance their effectiveness for clinical settings.
Stanford researchers have developed a method that not only detects B- and T-cell cancers but also is sufficiently sensitive to detect residual cancer in patients.